selected publications
-
Epsilon toxin-producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege.
The Journal of clinical investigation.
2023
Academic Article
GET IT
Times cited: 2 -
Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis.
Scientific reports.
2022
Academic Article
GET IT
Times cited: 8 -
A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis.
Molecular imaging and biology.
2020
Academic Article
GET IT
Times cited: 4 -
Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis Lesions.
Journal of neuroimaging : official journal of the American Society of Neuroimaging.
2020
Academic Article
GET IT
Times cited: 5 -
Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Journal of neurology.
2018
Academic Article
GET IT
Times cited: 1 -
Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.
Multiple sclerosis and related disorders.
2017
Academic Article
GET IT
Times cited: 23 -
An Acute Disseminated Encephalomyelitis-Like Illness in the Elderly: Neuroimaging and Neuropathology Findings.
2016
GET IT
Times cited: 9 -
Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.
Journal of neuroimaging : official journal of the American Society of Neuroimaging.
2016
Academic Article
GET IT
Times cited: 15 -
A study of patients with aggressive multiple sclerosis at disease onset.
Neuropsychiatric disease and treatment.
2016
Academic Article
GET IT
Times cited: 9 -
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
2016
GET IT
Times cited: 2 -
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
2015
GET IT
Times cited: 8 -
The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab.
2003
GET IT
Times cited: 73